Loading clinical trials...
Loading clinical trials...
Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice, Measured Using Patient-Reported Outcomes
Conditions
Interventions
Ustekinumab
Locations
23
Japan
Tokyo Medical and Dental University Hospital
Bunkyō City, Japan
Juntendo University Hospital
Bunkyō City, Japan
Chiba University Hospital
Chiba, Japan
Toho University Sakura Medical Center
Chiba, Japan
Kyushu University Hospital
Fukuoka, Japan
Fukuoka University Hospital
Fukuoka, Japan
Start Date
July 18, 2021
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2022
Last Updated
April 28, 2025
NCT07271069
NCT06975722
NCT07185009
NCT07184996
NCT07245394
NCT07089420
Lead Sponsor
Janssen Pharmaceutical K.K.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions